LEGEND BIOTECH CORP (LEGN)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$19.27+1.96%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge LEGEND BIOTECH CORP’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	386.03M
EPS	—	0.026
Annual ending 2026-12-31
Revenue	—	1.44B
EPS	—	-0.043
Annual ending 2027-12-31
Revenue	—	1.75B
EPS	—	0.541

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
CARVYKTI sales growth	Legend Biotech is nearing profitability with growing sales of CARVYKTI.	Intact	revenue falls below $1.4B in FY27	Revenue: $387.5M FY2026-Q2; GAAP. Published target: >= $1.8B revenue in FY27. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026387,500,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Positive clinical data and adoption trends for CARVYKTI	New data shows strong potential for CARVYKTI to treat cancer.	Improving	adoption trends weaken or new data disappoints	Qualitative: Positive adoption & data Q2 2026 revenue beat, first profitable quarter, and new CARVYKTI data boosted confidence and sales. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Adjusted profitability near term	A primary condition in LEGEND BIOTECH CORP's published investment case. The stated target is adjusted profit near break-even in FY26.	Intact	profitability delayed beyond FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPSUnavailable

$0.81 → Unavailable · observed estimates

FY2027 revenue$1.75B

$1.78B → $1.75B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$0.81	$1,775,081,608	5 / 10
2026-07-25	$0.81	$1,775,081,608	5 / 10
2026-07-26	$0.80	$1,779,373,937	5 / 10
2026-07-27	$0.80	$1,779,373,937	5 / 10
2026-07-28	$1.21	$1,818,295,890	5 / 11
2026-07-29	$1.21	$1,811,306,250	5 / 11
2026-07-30	$1.21	$1,811,306,250	5 / 11
2026-07-31	$1.21	$1,811,306,250	5 / 11
2026-08-01	$0.78	$1,773,904,008	5 / 9
2026-08-02	$1.21	$1,811,306,250	5 / 11
2026-08-03	$1.21	$1,811,306,250	5 / 11
2026-08-04	$1.21	$1,811,306,250	5 / 11
2026-08-05	$1.21	$1,811,306,250	5 / 11
2026-08-06	$0.78	$1,773,904,008	5 / 9
2026-08-07	$0.78	$1,773,904,008	5 / 9
2026-08-08	$1.21	$1,811,306,250	5 / 11
2026-08-09	$0.78	$1,773,904,008	5 / 9
2026-08-10	$1.21	$1,811,306,250	5 / 11
2026-08-12	$0.78	$1,773,904,008	5 / 9
2026-08-13	$0.78	$1,773,904,008	5 / 9
2026-08-14	$0.78	$1,773,904,008	5 / 9
2026-08-15	$0.78	$1,773,904,008	5 / 9
2026-08-16	$0.78	$1,773,904,008	5 / 9
2026-08-17	$0.78	$1,773,904,008	5 / 9
2026-08-18	$0.78	$1,773,904,008	5 / 9
2026-08-19	$0.78	$1,773,904,008	5 / 9
2026-08-20	Unavailable	$1,771,687,274	4 / 9
2026-08-21	Unavailable	$1,771,687,274	4 / 9
2026-08-22	Unavailable	$1,771,687,274	4 / 10
2026-08-23	Unavailable	$1,771,687,274	4 / 10
2026-08-24	Unavailable	$1,771,687,274	4 / 10
2026-08-25	Unavailable	$1,771,687,274	4 / 10
2026-08-26	Unavailable	$1,771,687,274	4 / 10
2026-08-27	Unavailable	$1,771,687,274	4 / 10
2026-08-28	Unavailable	$1,771,687,274	4 / 10
2026-08-29	Unavailable	$1,771,687,274	4 / 10
2026-08-30	Unavailable	$1,771,687,274	4 / 10
2026-08-31	Unavailable	$1,771,687,274	4 / 10
2026-09-01	Unavailable	$1,771,687,274	4 / 10
2026-09-02	Unavailable	$1,771,687,274	4 / 10
2026-09-03	Unavailable	$1,771,687,274	4 / 10
2026-09-04	Unavailable	$1,771,687,274	4 / 10
2026-09-05	Unavailable	$1,771,687,274	4 / 10
2026-09-06	Unavailable	$1,771,687,274	4 / 10
2026-09-07	Unavailable	$1,771,687,274	4 / 10
2026-09-08	Unavailable	$1,771,687,274	4 / 10
2026-09-09	Unavailable	$1,771,687,274	4 / 10
2026-09-10	Unavailable	$1,771,688,489	4 / 10
2026-09-11	Unavailable	$1,771,688,489	4 / 9
2026-09-12	Unavailable	$1,771,688,489	4 / 9
2026-09-13	Unavailable	$1,771,688,489	4 / 9
2026-09-14	Unavailable	$1,771,688,489	4 / 9
2026-09-15	Unavailable	$1,771,688,489	4 / 9
2026-09-16	Unavailable	$1,771,688,489	4 / 9
2026-09-17	Unavailable	$1,771,688,489	4 / 9
2026-09-18	Unavailable	$1,771,688,489	4 / 9
2026-09-19	Unavailable	$1,771,688,489	4 / 9
2026-09-20	Unavailable	$1,771,688,489	4 / 9
2026-09-21	Unavailable	$1,771,688,489	4 / 9
2026-09-22	Unavailable	$1,771,688,489	4 / 9
2026-09-23	Unavailable	$1,771,688,489	4 / 9
2026-09-24	Unavailable	$1,771,688,489	4 / 9
2026-09-25	Unavailable	$1,771,688,489	3 / 8
2026-09-26	Unavailable	$1,771,688,489	3 / 8
2026-09-27	Unavailable	$1,771,688,489	3 / 8
2026-09-28	Unavailable	$1,771,688,489	3 / 8
2026-09-29	Unavailable	$1,771,688,489	3 / 8
2026-09-30	Unavailable	$1,771,688,489	3 / 8
2026-10-01	Unavailable	$1,762,256,203	3 / 8
2026-10-02	Unavailable	$1,762,256,203	3 / 8
2026-10-03	Unavailable	$1,762,256,203	3 / 8
2026-10-04	Unavailable	$1,762,256,203	3 / 8
2026-10-05	Unavailable	$1,762,256,203	3 / 8
2026-10-06	Unavailable	$1,762,256,203	3 / 8
2026-10-07	Unavailable	$1,757,756,203	3 / 8
2026-10-08	Unavailable	$1,757,756,203	3 / 8
2026-10-09	Unavailable	$1,755,468,346	3 / 8
2026-10-10	Unavailable	$1,755,468,346	3 / 8
2026-10-11	Unavailable	$1,754,124,078	3 / 8
2026-10-12	Unavailable	$1,754,124,078	3 / 8
2026-10-13	Unavailable	$1,754,124,078	3 / 8
2026-10-14	Unavailable	$1,743,106,935	3 / 8
2026-10-15	Unavailable	$1,745,031,221	3 / 8
2026-10-16	Unavailable	$1,745,031,221	3 / 8
2026-10-17	Unavailable	$1,745,031,221	3 / 8
2026-10-18	Unavailable	$1,745,031,221	3 / 8
2026-10-19	Unavailable	$1,745,031,221	3 / 8
2026-10-20	Unavailable	$1,745,031,221	3 / 8
2026-10-21	Unavailable	$1,745,031,221	3 / 8
2026-10-22	Unavailable	$1,745,031,221	3 / 8
2026-10-23	Unavailable	$1,745,031,221	3 / 8
2026-10-24	Unavailable	$1,745,031,221	3 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	14	2
2026-06-01	13	2
2026-07-01	13	4
2026-08-01	11	5
2026-09-01	10	5
2026-10-01	8	5

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 8 Buy / Strong Buy · 5 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades4 maintains

Recent actions · Sep 25–Oct 24 · 4 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 8 · prior Jul 27

$59.00 → $56.00-5.1%

UBSSep 28 · prior Jul 24

$28.00 → $65.00+132.1%

$0$35.75$71.50

1 raises · 1 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

CARVYKTI sales growthRevenue: $387.5M
Adjusted profitability near termDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.0%Typical daily move · historical

Downside history

-53.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

LEGEND BIOTECH CORP outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk Healthcare investment with a cyclical exposure, not a clearly established durable compounder from the evidence available. The thesis state is insufficient because there is not enough recent financial-performance history to assess the business trend.

What's priced into LEGEND BIOTECH CORP

The snapshot provides no valuation level or market-expectations evidence, so it is not possible to judge whether LEGN is cheap, fair, or expensive versus peers. No pricing fragility signals fired, but that does not establish what the market already assumes.

What the fundamentals likely do

The Healthcare sector backdrop has improved, rising from 7.6 to 18.0, which may support the sector near term. Company-specific fundamentals remain hard to assess, and the next report carries elevated risk: the estimated miss probability is 45%, with recent peer misses noted.

What LEGEND BIOTECH CORP hinges on

Near term, a weakening jobs trend could increase recession concerns and pressure cyclical Healthcare names, while continued earnings strength and higher guidance from VRTX, REGN, and MRNA could sustain sector momentum. Misses or lower guidance from those bellwethers could weaken that support; the snapshot offers little direct evidence about LEGN’s own multi-year execution.